Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Sarcoma, Ewing 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Cyclophosphamide 7pembrolizumab 6Radiosurgery 6Specimen Handling 5Nivolumab 5Ifosfamide 5fludarabine phosphate 4Mycophenolic Acid 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Busulfan 4Sunitinib 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Melphalan 3Magnetic Resonance Spectroscopy 3Filgrastim 3Cyclosporine 3Cryosurgery 3Carboplatin 3trastuzumab deruxtecan 2tislelizumab 2sargramostim 2pazopanib 2fludarabine 2etoposide phosphate 2cabozantinib 2Whole-Body Irradiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × robatumumab × Sarcoma × Clear all
NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Merck Sharp & Dohme LLC

Phase 1 Terminated
4 enrolled 8 charts
CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡